转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

Clinica Chimica Acta：中国自身免疫性甲状腺疾病患儿血清IL-21和维生素D浓度的相关性

2020-06-24 MedSci原创 MedSci原创

自身免疫性甲状腺疾病
关注

小儿自身免疫性甲状腺疾病(AITD)的病因是多因素的，但主要与免疫功能紊乱有关。已有研究报道，白细胞介素-21 (IL-21)和维生素D在自身免疫性疾病中发挥关键作用。

小儿自身免疫性甲状腺疾病(AITD)的病因是多因素的，但主要与免疫功能紊乱有关。已有研究报道，白细胞介素-21 (IL-21)和维生素D在自身免疫性疾病中发挥关键作用。我们研究了IL与21、25(OH)D的相关性及其在AITD发病中的潜在作用。

南京医科大学附属无锡妇幼保健院于2017年9 - 11月至2019年9月共收治原发性Graves病(GD)患者54例， HT患者36例，健康受试者30例。测定血清中IL-21、25(OH)D、促甲状腺激素(TSH)、甲状腺过氧化物酶抗体(TPOAb)、TSH受体抗体(TRAb)和甲状腺球蛋白抗体(TGAb)的浓度。

研究结果显示，GD和HT患者血清中25(OH)D浓度低于对照组，IL-21浓度高于对照组。HT组血清25(OH)D浓度与TPOAb、TGAb呈负相关，而血清IL-21浓度与TPOAb、TGAb、TRAb呈正相关。治疗前后HT、GD患儿血清25(OH)D浓度与血清IL-21呈显著负相关。因此，我们研究了IL与21和25(OH)D的相关性，推断它们在AITD中发挥作用。此外，添加维生素D可以抑制TPOAb、TGAb和IL-21的表达浓度。

研究结果表明，IL-21和维生素D可能参与了AITD的发生和发展。以IL-21和维生素D为靶点可能是未来治疗AITD的一种有希望的方法。

原始出处：

Yaling Feng,Ting Qiu,Association of serum IL-21 and vitamin D concentrations in Chinese children with autoimmune thyroid disease

 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1778461, encodeId=c44a1e7846192, content=<a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9653, encryptionId=51f09653ba, topicName=IL-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=753a39257265, createdName=baoya, createdTime=Sun Nov 01 07:27:36 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974039, encodeId=de1419e403982, content=<a href='/topic/show?id=6bac863364e' target=_blank style='color:#2F92EE;'>#自身免疫性甲状腺疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86336, encryptionId=6bac863364e, topicName=自身免疫性甲状腺疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Mon Nov 09 18:27:36 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849955, encodeId=6dac184995577, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Aug 19 06:27:36 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837851, encodeId=d212183e8511a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Apr 01 22:27:36 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544648, encodeId=353e1544648af, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626062, encodeId=317f162606235, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799750, encodeId=542ae9975062, content=<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200315/6c52e73f687745e5b92987fb63ac6545/路径.png, createdBy=fb822254669, createdName=Ahui, createdTime=Thu Jun 25 09:34:48 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-11-01 baoya

    #IL-21#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1778461, encodeId=c44a1e7846192, content=<a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9653, encryptionId=51f09653ba, topicName=IL-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=753a39257265, createdName=baoya, createdTime=Sun Nov 01 07:27:36 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974039, encodeId=de1419e403982, content=<a href='/topic/show?id=6bac863364e' target=_blank style='color:#2F92EE;'>#自身免疫性甲状腺疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86336, encryptionId=6bac863364e, topicName=自身免疫性甲状腺疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Mon Nov 09 18:27:36 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849955, encodeId=6dac184995577, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Aug 19 06:27:36 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837851, encodeId=d212183e8511a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Apr 01 22:27:36 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544648, encodeId=353e1544648af, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626062, encodeId=317f162606235, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799750, encodeId=542ae9975062, content=<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200315/6c52e73f687745e5b92987fb63ac6545/路径.png, createdBy=fb822254669, createdName=Ahui, createdTime=Thu Jun 25 09:34:48 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-11-09 12498ca5m83暂无昵称

    #自身免疫性甲状腺疾病#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1778461, encodeId=c44a1e7846192, content=<a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9653, encryptionId=51f09653ba, topicName=IL-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=753a39257265, createdName=baoya, createdTime=Sun Nov 01 07:27:36 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974039, encodeId=de1419e403982, content=<a href='/topic/show?id=6bac863364e' target=_blank style='color:#2F92EE;'>#自身免疫性甲状腺疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86336, encryptionId=6bac863364e, topicName=自身免疫性甲状腺疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Mon Nov 09 18:27:36 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849955, encodeId=6dac184995577, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Aug 19 06:27:36 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837851, encodeId=d212183e8511a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Apr 01 22:27:36 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544648, encodeId=353e1544648af, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626062, encodeId=317f162606235, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799750, encodeId=542ae9975062, content=<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200315/6c52e73f687745e5b92987fb63ac6545/路径.png, createdBy=fb822254669, createdName=Ahui, createdTime=Thu Jun 25 09:34:48 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-08-19 windight

    #CTA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1778461, encodeId=c44a1e7846192, content=<a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9653, encryptionId=51f09653ba, topicName=IL-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=753a39257265, createdName=baoya, createdTime=Sun Nov 01 07:27:36 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974039, encodeId=de1419e403982, content=<a href='/topic/show?id=6bac863364e' target=_blank style='color:#2F92EE;'>#自身免疫性甲状腺疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86336, encryptionId=6bac863364e, topicName=自身免疫性甲状腺疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Mon Nov 09 18:27:36 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849955, encodeId=6dac184995577, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Aug 19 06:27:36 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837851, encodeId=d212183e8511a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Apr 01 22:27:36 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544648, encodeId=353e1544648af, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626062, encodeId=317f162606235, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799750, encodeId=542ae9975062, content=<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200315/6c52e73f687745e5b92987fb63ac6545/路径.png, createdBy=fb822254669, createdName=Ahui, createdTime=Thu Jun 25 09:34:48 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2021-04-01 shenxlcyp

    #相关性#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1778461, encodeId=c44a1e7846192, content=<a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9653, encryptionId=51f09653ba, topicName=IL-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=753a39257265, createdName=baoya, createdTime=Sun Nov 01 07:27:36 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974039, encodeId=de1419e403982, content=<a href='/topic/show?id=6bac863364e' target=_blank style='color:#2F92EE;'>#自身免疫性甲状腺疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86336, encryptionId=6bac863364e, topicName=自身免疫性甲状腺疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Mon Nov 09 18:27:36 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849955, encodeId=6dac184995577, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Aug 19 06:27:36 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837851, encodeId=d212183e8511a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Apr 01 22:27:36 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544648, encodeId=353e1544648af, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626062, encodeId=317f162606235, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799750, encodeId=542ae9975062, content=<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200315/6c52e73f687745e5b92987fb63ac6545/路径.png, createdBy=fb822254669, createdName=Ahui, createdTime=Thu Jun 25 09:34:48 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-06-26 12498974m55暂无昵称

    #浓度#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1778461, encodeId=c44a1e7846192, content=<a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9653, encryptionId=51f09653ba, topicName=IL-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=753a39257265, createdName=baoya, createdTime=Sun Nov 01 07:27:36 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974039, encodeId=de1419e403982, content=<a href='/topic/show?id=6bac863364e' target=_blank style='color:#2F92EE;'>#自身免疫性甲状腺疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86336, encryptionId=6bac863364e, topicName=自身免疫性甲状腺疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Mon Nov 09 18:27:36 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849955, encodeId=6dac184995577, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Aug 19 06:27:36 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837851, encodeId=d212183e8511a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Apr 01 22:27:36 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544648, encodeId=353e1544648af, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626062, encodeId=317f162606235, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799750, encodeId=542ae9975062, content=<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200315/6c52e73f687745e5b92987fb63ac6545/路径.png, createdBy=fb822254669, createdName=Ahui, createdTime=Thu Jun 25 09:34:48 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-06-26 tomyang93

    #IL-2#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1778461, encodeId=c44a1e7846192, content=<a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9653, encryptionId=51f09653ba, topicName=IL-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=753a39257265, createdName=baoya, createdTime=Sun Nov 01 07:27:36 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974039, encodeId=de1419e403982, content=<a href='/topic/show?id=6bac863364e' target=_blank style='color:#2F92EE;'>#自身免疫性甲状腺疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86336, encryptionId=6bac863364e, topicName=自身免疫性甲状腺疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Mon Nov 09 18:27:36 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849955, encodeId=6dac184995577, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Aug 19 06:27:36 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837851, encodeId=d212183e8511a, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Apr 01 22:27:36 CST 2021, time=2021-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544648, encodeId=353e1544648af, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626062, encodeId=317f162606235, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Fri Jun 26 13:27:36 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799750, encodeId=542ae9975062, content=<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200315/6c52e73f687745e5b92987fb63ac6545/路径.png, createdBy=fb822254669, createdName=Ahui, createdTime=Thu Jun 25 09:34:48 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-06-25 Ahui

    #维生素D#

    0

相关资讯

CCLM：miRNA在检验医学中的应用—microRNA表达水平与自身免疫性甲状腺疾病发病机制的关联

微小RNA（miRNA）在血液中循环并负调节mRNA的表达。一些miRNA与自身免疫性甲状腺疾病（AITD）的发生相关。 然而，关于miRNA表达与AITD的发病机制和循环miRNA的生理变化之间的关联的报道很少。

JCEM：用于评估自身免疫性甲状腺疾病风险和严重性的miRNA标签

众所周知循环miRNA因为其作为新型生物标记物和治疗靶标的潜在作用，正在成为一个研究热点，然而其在自身免疫性甲状腺疾病（AITD）中所起的作用还未得到充分研究。2018年1月9日在JCEM上发表的一篇文章则通过下一代测序比较AITD患者和对照者甲状腺组织中的miRNA的表达谱，并用qRT-PCR证实，进一步验证其血清样本中的发现。

JCEM：甲状腺和胰岛自身抗体预测1型糖尿病患者的自身免疫性甲状腺疾病

对1型糖尿病儿童和年轻成人患者进行自身免疫性甲状腺疾病的筛查是很重要的。 本研究的目的是，评估甲状腺自身抗体、甲状腺功能、胰岛自身抗体和HLA-DQ对1型糖尿病患者的自身免疫性甲状腺疾病的预测价值。 研究纳入了2433例1型糖尿病儿童患者，检测患儿的抗甲状腺过氧化物酶抗体（TPOAb）、甲状腺球蛋白抗体（TGAb）、谷氨酸脱羧酶抗体（GADA）、胰岛素（IAA）、胰岛素瘤相关蛋白-2（